Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLB1004 in advanced NSCLC
NCT05347628Phase 1Unknown
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Apr 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of andamertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Avistone Biotechnology Co., Ltd. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 2 years, Dose-limiting toxicities at 28 days and 2 more. Status: unknown.
02
Drugs
andamertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05347628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347628.